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ABSTrACT
Background. Albuminuria is an early clinical indicator of 
diabetic kidney disease (DKD). however, it has several 
limitations. The aim of this study was to evaluate the 
plasma microrNA-192 (mirNA-192) expression and 
its diagnostic performance in patients with type 2 
diabetes mellitus (T2DM) and DKD.
Methods. In this case-control study, 75 subjects were 
included into 3 groups: group (1): 20 patients with 
T2DM and UACr (urinary albumin creatinine ratio) 
< 30 mg/gm, group (2): 30 patients with T2DM and 
ACr ≥ 30 mg/gm, and group (3): 25 healthy controls. 
Patients were recruited from the outpatient clinic of 
the Diabetes unit at our institution. real-Time Quan-
titative reverse Transcription PCr was used to assess 
plasma mirNA-192 expression. 
Results. Plasma miRNA-192 was significantly higher in 
T2DM patients with DKD compared to those with nor-
mal UAE. Additionally, in patients with T2DM, plasma 
mirNA-192 was positively correlated with UACr. The 
rOC curve analysis for mirNA-192 plasma expression 
in patients with T2DM, revealed that mirNA-192 had 
a good diagnostic performance (AUC = 0.778) to define 
T2DM patients with DKD.
Conclusion. Plasma expression of mirNA-192 was able 
to discriminate increased UAE among patients with 
T2DM; suggesting a promising role for mirNA-192 as 
a potential biomarker for DKD. (Clin Diabetol 2020; 9; 
6: 454–460)
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Introduction
Diabetes mellitus (DM) is an expanding universal 
health problem; according to the International Diabetes 
Federation (IDF), the prevalence of DM worldwide is 
8.3% expected to reach 9.8% by 2045 [1]. This continu-
ously growing prevalence, is mainly attributed to the 
increase in type 2 diabetes mellitus (T2DM), the most 
common type of DM representing 90% of cases [2]. In 
Egypt, the prevalence of T2DM is around 15.6% among 
adults; thus Egypt is ranked the ninth country world-
wide regarding the number of patients with T2DM [1]. 
Diabetic kidney disease (DKD) is not only the most 
frequent microvascular complication of DM, but also, it 
is the leading cause of end-stage renal disease (ESRD), 
accounting for 50% of cases [2]. 
Despite being an early clinical indicator of DKD, 
albuminuria, detected by urinary albumin creatinine 
ratio (UACR), has some limitations [3]. Diabetic patients 
may present with impaired renal function without 
significant increases in albuminuria [4]. Moreover, 
albuminuria is not a perfect prognostic indicator for 
DKD progression, as the degree of albuminuria does 
not closely correlate with the decrease in glomerular 
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filtration rate (GFR) [5]. In addition, some structural 
alterations associated with DKD may precede albumi-
nuria [6, 7]. Furthermore, 30% only of patients with 
moderately increased albuminuria (30–300 mg/gm) 
progress to overt nephropathy [8]. Accordingly, there 
is a call for identifying a biomarker which efficiently 
allows early diagnosis for more effective therapeutic 
interventions, and acts as a reasonable prognostic 
indicator for disease progression.
MicroRNAs (miRNAs) are highly conserved non-
coding RNAs, consisting of 18–24 nucleotides and 
exerting their role in controlling human gene expres-
sion through post-transcriptional gene regulation or 
silencing [9]. Circulating miRNAs are characterized by 
high stability [10], reproducibility [11] and available de-
tection by sensitive and specific quantitative real-time 
polymerase chain reaction (qRT-PCR) [12], therefore 
they are appealing biomarkers for a variety of diseases.
MicroRNA-192 is one of the most commonly ex-
pressed miRNAs in the renal cortex [13]. Several studies 
have reported an important role for miRNA-192 in the 
fibrogenesis process in DKD induced by transforming 
growth factor-b1 (TGF-b1). However, the results of these 
studies are conflicting. Owing to these contradicting 
reports about the role of miRNA-192 in identifying 
DKD, together with the need for an efficient diagnostic 
marker; we were directed to carry out the present study.
subjects
In this case-control study 75 subjects were included 
and divided into 3 groups: group (1): 20 patients with 
T2DM without DKD, group (2): 30 patients with T2DM 
and DKD, and group (3): 25 healthy subjects of matched 
age and sex as a control group. T2DM and DKD were 
defined according to the diagnostic criteria of American 
Diabetes Association (ADA) [14, 15]. 
Patients were recruited from the outpatient clinic of 
the Diabetes and metabolism unit at Alexandria Main 
University hospital, in the period between December 
2018 and August 2019. Patients with acute illness at 
time of the study, hepatic disease, cardiovascular dis-
ease, hematological disorders, malignancy, systemic 
chronic inflammation, history of hemodialysis or renal 
transplantation and patients using nephrotoxic drugs 
or corticosteroids were excluded.
An informed consent was obtained from each 
patient after explaining the nature and the aim of the 
study. The current study was done according to the 
Ethical Principles for Medical Research Involving Human 
Subjects defined in the Helsinki Declaration in 1975 
(revised in 2008). The approval of the ethics commit-
tee of Faculty of Medicine, Alexandria University was 
obtained in 2018. 
Methods
laboratory investigations
Fasting plasma glucose (FPG), fasting insulin, gly-
cated haemoglobin (HbA1c) and UACR were determined 
by commercial enzymatic methods. Insulin resistance 
was calculated on the basis of the homeostasis model 
assessment of insulin resistance (HOMA-IR), using the 
following formula: [HOMA-IR = (fasting insulin in uIU/L 
× fasting glucose in mg/dL)/405] [16]. 
Molecular analysis: Relative quantification of 
mirNA-192 expression using real-Time qrT-PCr [17] 
was done through 3 steps:
I. Total RNA extraction: Purification of cell-free to-
tal RNA from plasma, which includes small RNAs 
as miRNAs, was done using the miRNeasy Se-
rum/Plasma Kit (Qiagen, Germany). Exogenous 
oligonucleotide (cel-miR-39) was added in order 
to monitor miRNA analysis (RNA extraction and 
reverse-transcription real time PCR).
II. Real-time qRT-PCR, in 2 steps:
1. Reverse transcription (RT): complementary 
DNA was synthesized from purified RNA 
samples using the miScript II RT Kit (Qiagen, 
Germany) according to the manufacturer’s 
protocol. 
2. Real-time PCR quantification of mature mi-
RNA-192: using target-specific miScript 
Primer Assays (forward primers) (Qiagen, 
Germany) and the miScript SYBR Green PCR 
Kit (Qiagen, Germany), which contains the 
miScript Universal Primer (reverse primer) and 
QuantiTect SYBR Green PCR Master Mix.
III. Calculation relative quantification of miRNA-192 
was determined using comparative CT method 
(2–DDCT) normalized to RNU6B as an endogenous 
control.
Statistical analysis of the data 
Data were fed to the computer and analyzed us-
ing IBM SPSS software package version 20.0. (Armonk, 
NY: IBM Corp). Qualitative data were described using 
number and percent. Quantitative data were described 
using range (minimum and maximum), mean, standard 
deviation and median. Chi-square test for categorical 
variables, to compare between different groups. Mann-
-Whitney test for abnormally distributed quantitative 
variables, to compare between two studied groups. 
F-test (ANOVA) for normally distributed quantitative 
variables, to compare between more than two groups, 
and post hoc test (Tukey) for pairwise comparisons. 
Kruskal Wallis test for abnormally distributed quanti-
tative variables, to compare between more than two 
studied groups, and post hoc (Dunn’s multiple com-
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parisons test) for pairwise comparisons. Spearman coef-
ficient to correlate between two distributed abnormally 
quantitative variables. Receiver operating characteristic 
curve (ROC) It is generated by plotting sensitivity (TP) 
on Y axis versus 1-specificity (FP) on X axis at different 
cut off values. The area under the ROC curve (AUC) 
denotes the diagnostic performance of the test. Area 
more than 50% gives acceptable performance and area 
about 100% is the best performance for the test. The 
ROC curve allows also a comparison of performance 
between two tests. Significance of the obtained results 
was judged at the 5% level.
Results
The 3 study groups were age- and sex-matched and 
there was no statistically significant difference between 
the 2 groups of diabetic patients regarding diabetes 
duration (Table 1).
The FPG and HOMA-IR were significantly lower 
in T2DM patients with normal UAE compared to 
those with increased UAE (P = 0.039 and P = 0.008 
respectively). On the contrary, there was no significant 
difference between both groups regarding HbA1c 
(P = 0.452). 
Regarding the plasma expression of miRNA-192 
was significantly higher in diabetic patients with 
normal and increased UAE compared to the controls 
(P < 0.001). Moreover, plasma miRNA-192 expression 
was significantly higher in T2DM patients with DKD 
(UACR ≥ 30) compared to T2DM patients with normal 
UAE (P = 0.025). (Table 2, Fig. 1).
Additionally, in patients with T2DM, the plasma 
expression of miRNA-192 was positively correlated 
with FPG (r = 0.598, P < 0.001), HOMA-IR (r = 0.565, 
P < 0.001), diabetes duration (r = 0.450, P < 0.001) 
and UACR (r = 0.506, P < 0.001) (Table 3).
Table 2. Comparison between the study groups according to the studied parameters 
uACr [mg/gm]
< 30 (n = 20) ≥ 30 (n = 30) Control (n = 25) Test of sig. P
FPG [mg/dL] 156 (72–263) 210.50 (105–325) 87 (75–99) H = 46.43* < 0.001*
P1 = 0.039*, P2 < 0.001*,P3 < 0.001*
F insulin [uIU/mL] 14.7 (2.3–23.4) 17.8 (7.27–42) 7.90 (1.20–41.50) H = 11.025* 0.004*
P1 = 0.122, P2 = 0.132, P3 = 0.001*
HOMA-IR 4.14 (1.39–12.96) 9.91 (3.46–22.6) 1.70 (0.20–9.80) H = 34.14* < 0.001*
P1 = 0.008*, P2 = 0.007*, P3 < 0.001*
HbA1c (%) 9.98 ± 2.30 9.56 ± 2.41 5.29 ± 0.14 F = 44.004* < 0.001*
P1 = 0.452, P2 < 0.001*,P3 < 0.001*
MicroRNA 192 2.08 (1.0–2.99) 3.12 (1.36–4.80) 0.82 (0.23–1.05) H = 53.74* < 0.001*
P1 = 0.025*, P2 < 0.001*, P3 < 0.001*
F — F for ANOVA test, Pairwise comparison bet. each 2 groups was done using Post Hoc Test (Tukey); H — H for Kruskal Wallis test, Pairwise comparison 
bet. each 2 groups was done using Post Hoc Test (Dunn’s for multiple comparisons test); P — P value for comparing between the studied groups; P1 —  
P value for comparing between < 30 and ≥ 30; P2 — P value for comparing between < 30 and control; P3 — P value for comparing between ≥ 30 and  
control; *Statistically significant at P ≤ 0.05 
Normally Quantitative data was expressed using Mean ± SD
Abnormally Quantitative data was expressed using Median (Min–Max)
Table 1. Comparison between the studied groups according to demographic data
uACr [mg/gm] Control (n = 25) Test of sig. P
< 30 (n = 20) ≥ 30 (n = 30)
Sex
Male 11 (55%) 16 (53.3%) 12 (48%)
c2 = 0.254
0.881
Female 9 (45%) 14 (46.7%) 13 (52%)
Age (years) 48.75 ± 2.94 47.43 ± 3.24 46.48 ± 3.93 F = 2.458 0.093
Diabetes duration (years) 5.50 (1–12) 7.0 (1–16) – U = 237.0 0.211
c2 — Chi square test; F — F for ANOVA; test U — Mann Whitney test; P — P value for comparing between the studied groups
Qualitative data were described using number and percentage
Normally Quantitative data was expressed using Mean ± SD
Abnormally Quantitative data was expressed using Median (Min–Max)
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Furthermore, the ROC curve analysis for miRNA-192 
plasma expression in patients with T2DM, revealed that 
miRNA-192 had a good diagnostic performance (AUC 
0.778, 95% C.I 0.652–0.904) to discriminate T2DM 
patients with DKD from those with normal UAE. Also, 
according to the ROC curve, at a cutoff value > 2.7549, 
plasma miRNA-192 expression had 63.33% sensitivity 
and specificity was 90% (Fig. 2).
Discussion
DKD is the most frequent diabetic microvascular 
complication and the most common cause of chronic 
kidney disease worldwide [18]. Despite being the most 
widely used test for early detection of DKD, albuminu-
ria has multiple drawbacks [5]. This triggers exploring 
new biomarkers for the identifying early diagnosis and 
prognosis of DKD.
MicroRNA- 192 is among miRNAs which are highly 
expressed in the human kidneys, and it has an impor-
tant role in normal kidney function [19]. An important 
role for miRNA-192 in the fibrogenesis process in DKD 
has been suggested in several studies. However, the 
results of these studies are inconsistent.
Kato et al. [20], in 2007, provided the first land-
mark report about the role of miRNA in DKD, as they 
found that miRNA-192 levels significantly increased 
in glomeruli of diabetic mice parallel to the increased 
TGF-b1 and collagen 1a2 levels.
In 2010, Kato and colleagues [21] found that in 
mouse mesangial cells, TGF-b1 was upregulated by 
miRNA-192. In addition, inhibition of miRNA-192 de-
creased the expression of miR-200b/c, collagen 1a2, 
collagen 4a1 and TGF-b1 in mouse mesangial cells, and 
in mouse kidney cortex.
In line with these results, Putta et al. [22] reported 
that in in cultured glomerular mesangial cells and in 
glomeruli from diabetic mice, TGF-b1 upregulated 
miRNA-192. Furthermore, they found that miRNA-192 
Figure 2. ROC curve for microRNA-192 to predict T2DM pa-
tients with uACR ≥ 30 mg/gm





































Table 3. Correlation between mirNA 192 and different studied parameters
mirNA 192
ACr < 30 mg/gm 
(n = 20)
ACr ≥ 30 mg/gm 
(n = 30)
Total cases with T2DM 
(n = 50)
rs P rs P rs P
FPG [mg/dL] 0.598* 0.005* 0.535* 0.002* 0.598* < 0.001*
HbA1c (%) –0.154 0.518 –0.328 0.077 –0.244 0.087
DM duration (years) 0.542* 0.013* 0.339 0.067 0.450* 0.001*
uACR [mg/gm] 0.189 0.426 0.247 0.189 0.506* < 0.001*
HOMA-IR 0.293 0.210 0.608* < 0.001* 0.565* < 0.001*
rs — Spearman coefficient; *Statistically significant at P ≤ 0.05
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increased collagen expression through targeting the 
E-box repressors Zeb1/2. Additionally, locked nucleic 
acid, an inhibitor of miRNA-192, significantly increased 
Zeb1/2 and decreased expression of collagen, TGF-b1 
and fibronectin in the kidneys of diabetic mice. Moreo-
ver, inhibition of miRNA-192 decreased proteinuria in 
these mice.
Contrariwise, Krupa and colleagues [23] reported 
that decreased miRNA-192 expression was associated 
with tubulointerstitial fibrosis and low GFR in tissues 
of renal biopsies from patients with DKD. Moreover, 
reduced miRNA-192 expression in proximal tubular cells 
was observed after treatment with TGF-b1. 
The observed contradictory between the results of 
the aforementioned studies may be attributed to the 
different models, cell lines and time points that were 
used. It also can be suggested that these discrepancies 
may indicate a cell-type-specific regulation; such that 
upregulated glomerular miRNA-192 enhances matrix 
deposition, whereas miRNA-192 downregulation in 
renal tubules, facilitates epithelial to mesenchymal 
transition [24]. 
Conflicting results regarding the role miRNA-192 
in DKD were not only reported in studies of cultured 
tissues and mice, but also studies involving patients 
with DKD revealed similar contradiction. 
In the current work, the results showed that 
plasma miRNA-192 was significantly higher in T2DM 
patients with DKD compared to those with normal UAE. 
Moreover, in patients with T2DM, plasma miRNA-192 
was positively correlated with UACR. The ROC curve 
analysis for miRNA-192 plasma expression in patients 
with T2DM, revealed that miRNA-192 had a good diag-
nostic performance to define T2DM patients with DKD.
In line with our results, Saadi et al. [25], demon-
strated that serum miRNA-192 was significantly higher 
in diabetic patients with lower GFR and higher UACR.
Chien et al. [26] reported that there was no 
significant difference in serum miRNA-192 between 
T2DM subjects with and without DKD. However, serum 
miRNA-192 was significantly higher in patients with 
markedly increased UAE than in patients with moder-
ately increased UAE.
Conversely, in a study of patients with T2DM with 
different levels of UAE, Jia et al. [27] reported that 
miRNA-192 levels were significantly higher in urine 
extracellular vesicles of patients with moderately in-
creased UAE compared to normoalbuminuric and con-
trol subjects. Moreover, miRNA was positively correlated 
with albuminuria and TGF-b1 in patients with normal 
and moderately increased UAE. Additionally, the ROC 
curve analysis showed AUC of 0.802 for miRNA-192 
in discriminating T2DM patients with normal UAE 
from those with moderately increased UAE. However, 
miRNA-192 levels in urine extracellular vesicles was 
decreased in patients with markedly increased UAE.
On the other hand, in disagreement with the 
results of the current study, Ma et al. [13] found that 
miRNA-192 in patients with markedly increased UAE 
was significantly lower than those with moderately 
increased UAE. Additionally, miRNA-192 was in patients 
with moderately increased UAE compared to those with 
normal UAE. Furthermore, the expression of miR-192 
was negatively correlated with TGF-b1.
Comparably, in study by Al-Kafaji and colleagues, 
miRNA-192 expression was 2.4-fold lower in the mi-
croalbuminuric patients compared to the normoalbu-
minuric group. Moreover, it was significantly lower by 
19-folds in patients with macroalbuminuria compared 
to the normoalbuminuric patients. Additionally, the 
AUC of the ROC curve for miRNA was 0.70 regarding 
detection of increased UAE [28]. 
Similarly, A. El-Monem et al. [29] found that 
miRNA-192 expression was significantly lower in 
T2DM patients with microalbuminuria than those with 
normoalbuminuria. Microalbuminuria in patients with 
T2DM was accompanied by significantly higher serum 
level of IL-18 and TGF-b. Moreover, the ROC curve of 
miRNA-192 in patients with microalbuminuria showed 
very good performance with AUC of 0.946. 
Despite their conflicting results, the current work 
together with the aforementioned studies suggest a 
significant importance for miRNA-192 in identifying 
DKD. Nevertheless, further research should be carried 
out on larger number of patients with different eth-
nicities and different stages of DKD in order to define 
clearly the role of miRNA-192 in pathogenesis of DKD 
and its ability to diagnose and predict the clinical 
course of DKD.
The current work proved a high specificity for 
miRNA-192. Different methods have been endorsed by 
international guidelines to screen for DKD. Spot urine 
sample UACR is a simple easy method for screening, 
but many limitations are there. In addition to the in-
traday variability and the need for repeated measures 
for conformation, false-positive rates were found to 
increase with age approaching 30%, so it is considered 
a poor predictor of quantitative AER, and so, should 
not be used as a diagnostic test [30]. 
Again, Although GFR is commonly accepted as 
the best overall index of kidney function, it is gener-
ally reduced after widespread structural damage, so its 
sensitivity to early detect renal damage is questionable. 
it has been reported to underestimate the renal func-
tion in some populations, especially in patients with 
near-normal renal function [31]. 
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Conclusion
In this case-control study, the plasma expression of 
miRNA-192 was significantly higher in T2DM patients 
with DKD compared to those with normal UAE. Addi-
tionally, in patients with T2DM, the plasma expression 
of miRNA-192 was positively correlated with albumi-
nuria and displayed good diagnostic performance in 
discriminating patients with DKD in T2DM. Thus, the 
plasma expression of miRNA-192 was able to discrimi-
nate increased UAE among patients with T2DM; sug-
gesting a promising role for miRNA-192 as a potential 
biomarker for DKD.
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